The NIRSE-GAL study shows in real time the evolution of the coverage achieved by immunisation with Nirsevimab in children and compares RSV admissions in different population groups of children and adults in Galicia in Spain with previous years.

Since 2018, the work of the European Commission on vaccination has been guided by the Council Recommendation on strengthened cooperation against vaccine-preventable diseases. The aim of this report is to support possible policy developments in the future.

Protecting infants from RSV with new tools: vaccines for pregnant women and use of monoclonal antibodies have been approved for use in the European Union to prevent RSV among young children. Are those tools working?

With the support of Sanofi, the Influenza Diabetes Community conducted a communications campaign to raise awareness of the impact of influenza on diabetes patients.

Chaired by DG SANTE, EU Member States agreed on prioritising for 2024-2026: health promotion & prevention of non-communicable diseases; healthy longevity/lifelong prevention; vaccine-preventable diseases & vaccination; and long COVID, amongst others.

Accurate information on the health burden of vaccine-preventable infections (VPIs) is needed to support evidence-informed vaccine policy recommendations and programmes in Europe.

Vaccines that protect against any H1N1 influenza A virus strain would beadvantageous for use in pigs and humans.

An independent information document for nurses

Winter may be long gone and summer just around the corner, but the flu season is dragging on with all states continuing to record cases.

Infants younger than 6 months are at risk of severe SARS-CoV-2 infection.

European health ministers agreed on a target of vaccinating 75% of older people in 2009 ‒ almost all countries are still falling short.

On February 2023, the French National Authority for Health (HAS) recommended extending flu shots to children aged 2-17 years without comorbidities.